Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering Drugs (CIMT)
Prevalence of Atherosclerotic Disease in Asian Subjects Not on Lipid-lowering Agents, But With at Least Two CVD Risk Factors
Sponsor: AstraZeneca
A NA clinical study on Cardiovascular Disease, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 11 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Mar 2026 — Present [monthly]
Completed NA
-
Feb 2026 — Present [monthly]
Completed NA
-
Feb 2026 — Present [monthly]
Completed NA
-
Jan 2026 — Present [monthly]
Completed NA
-
Dec 2025 — Feb 2026 [monthly]
Completed NA
▶ Show 6 earlier versions
-
Sep 2025 — Dec 2025 [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Oct 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bandung-Jawa, Indonesia , Beijing, China , Denpasar, Indonesia , Gūrgaon, India , Hanoi, Vietnam , Ho Chi Minh City, Vietnam , Jaipur, India , Kaohsiung, Taiwan , Kuching, Malaysia , Manila, Philippines and 9 more locations